Evidence map›Paper›PMID 24567719›Full record

ArticleFrontiers in pharmacology2014

Chemogenomics knowledgebased polypharmacology analyses of drug abuse related G-protein coupled receptors and their ligands.

Xiang-Qun Xie, Lirong Wang, Haibin Liu, Qin Ouyang, Cheng Fang, Weiwei Su

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. DAKB-GPCRs: An Integrated Computational Platform for Drug Abuse Related GPCRs.Journal of chemical information and modeling · 2019
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Systems Pharmacology Links GPCRs with Retinal Degenerative Disorders.Annual review of pharmacology and toxicology · 2016
    Review
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Xiang-Qun XieDepartment of Pharmaceutical Sciences, Computational Chemical Genomics Screening Center, School of Pharmacy, University of Pittsburgh Pittsburgh, PA, USA ; Center for Chemical Methodologies and Library Development (UPCMLD) and Department of Chemistry, University of Pittsburgh Pittsburgh, PA, USA ; Drug Discovery Institute, University of Pittsburgh Pittsburgh, PA, USA ; Departments of Computational and Systems Biology, University of Pittsburgh Pittsburgh, PA, USA.
Lirong WangDepartment of Pharmaceutical Sciences, Computational Chemical Genomics Screening Center, School of Pharmacy, University of Pittsburgh Pittsburgh, PA, USA ; Center for Chemical Methodologies and Library Development (UPCMLD) and Department of Chemistry, University of Pittsburgh Pittsburgh, PA, USA ; Drug Discovery Institute, University of Pittsburgh Pittsburgh, PA, USA.
Haibin LiuDepartment of Pharmaceutical Sciences, Computational Chemical Genomics Screening Center, School of Pharmacy, University of Pittsburgh Pittsburgh, PA, USA ; Guangzhou Quality R&D Center of Traditional Chinese Medicine, School of Life Sciences, Sun Yat-Sen University Guangzhou, China.
Qin OuyangDepartment of Pharmaceutical Sciences, Computational Chemical Genomics Screening Center, School of Pharmacy, University of Pittsburgh Pittsburgh, PA, USA ; Center for Chemical Methodologies and Library Development (UPCMLD) and Department of Chemistry, University of Pittsburgh Pittsburgh, PA, USA ; Drug Discovery Institute, University of Pittsburgh Pittsburgh, PA, USA.
Cheng FangDepartment of Pharmaceutical Sciences, Computational Chemical Genomics Screening Center, School of Pharmacy, University of Pittsburgh Pittsburgh, PA, USA ; Center for Chemical Methodologies and Library Development (UPCMLD) and Department of Chemistry, University of Pittsburgh Pittsburgh, PA, USA ; Drug Discovery Institute, University of Pittsburgh Pittsburgh, PA, USA.
Weiwei SuGuangzhou Quality R&D Center of Traditional Chinese Medicine, School of Life Sciences, Sun Yat-Sen University Guangzhou, China.
Discovery Institute · USSun Yat-sen University · CNUniversity of Pittsburgh · US

Funding

NIDA Center of Excellence OF Computational Drug Abuse Research (CDAR)P30DA035778 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BAHAR, IVET, XIE, XIANG-QUN · 2014 to 2018
$5.4M
Structure/Function of the CB2 Receptor Binding and G-protein Recognition PocketsR01DA025612 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI XIE, XIANG-QUN · 2010 to 2014
$1.7M
Screen and Design p18 Chemical Probes for Hematopoietic Stem Cell Self-RenewalR21HL109654 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI XIE, XIANG-QUN · 2011 to 2012
$413k
NHLBI NIH HHS R21 HL109654NIDA NIH HHS P30 DA035778NIDA NIH HHS R01 DA025612
6 · The paper itself

Abstract

Drug abuse (DA) and addiction is a complex illness, broadly viewed as a neurobiological impairment with genetic and environmental factors that influence its development and manifestation. Abused substances can disrupt the activity of neurons by interacting with many proteins, particularly G-protein coupled receptors (GPCRs). A few medicines that target the central nervous system (CNS) can also modulate DA related proteins, such as GPCRs, which can act in conjunction with the controlled psychoactive substance(s) and increase side effects. To fully explore the molecular interaction networks that underlie DA and to effectively modulate the GPCRs in these networks with small molecules for DA treatment, we built a drug-abuse domain specific chemogenomics knowledgebase (DA-KB) to centralize the reported chemogenomics research information related to DA and CNS disorders in an effort to benefit researchers across a broad range of disciplines. We then focus on the analysis of GPCRs as many of them are closely related with DA. Their distribution in human tissues was also analyzed for the study of side effects caused by abused drugs. We further implement our computational algorithms/tools to explore DA targets, DA mechanisms and pathways involved in polydrug addiction and to explore polypharmacological effects of the GPCR ligands. Finally, the polypharmacology effects of GPCRs-targeted medicines for DA treatment were investigated and such effects can be exploited for the development of drugs with polypharmacophore for DA intervention. The chemogenomics database and the analysis tools will help us better understand the mechanism of drugs abuse and facilitate to design new medications for system pharmacotherapy of DA.

Indexed as

chemogenomicscloud computationdrug abuseGPCRspolydrug addictionpolypharmacologysystems pharmacologytarget prediction

Identifiers

PMID24567719
PMCPMC3915241
OpenAlexW1987583705

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.